73625-85-1

Upstream product

• 23510-95-4 4-benzoyloxycyclohexanone 
• 100-39-0 benzyl bromide 
• 79-06-1 2-propenamide 
• 73625-23-7 6-benzoyloxy-3,4,5,6,7,8-hexahydro-1H-quinolin-2-one 
• 98-88-4 benzoyl chloride 
• 13482-22-9 4-hydroxycyclohexanone 
• 52351-46-9 4-benzoyloxy-1-pyrrolidin-1-yl-cyclohexene 

Downstream Products

• 74196-93-3 quinpirole 
• 73625-80-6 1-benzyl-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquinoline 

Relevant academic research and scientific papers

SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS

Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.

Bicyclic and tricyclic ergoline partial structures: Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists

It is proposed, based upon comparisons with apomorphine, that the rigid pyrroleethylamine moiety of the ergolines is the portion of the molecule responsible for dopamine agonist activity. In support of this hypothesis, bicyclic and tricyclic ergoline part

Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines

Octahydropyrazolo[3,4-g]quinolines, dopamine agonists, useful in treatment of Parkinsonism and in inhibiting secretion of prolactin.